Webster RP, Roberts VH, Myatt L
Motivation While semaglutides economic success as a GLP-1R agonist sets a benchmark for the market, it will not be the best GLP-1R agonist in glycemic control and weight management, and there is still need for continued innovation in the progression of peptide-based therapies for metabolic disorders, as exemplified in the history of insulin of continued design and development of analogues with enhanced pharmacological profiles [1, 3234]
Requires surgery, lifestyle commitment, vitamin/protein attention, and careful follow-up
Understanding general peptide response timelines contextualizes expectations across different applications
What if I cross time zones
doi: 10.1038/nature11813 87 WangSXiaPChenYQuYXiongZYeBet al